Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells
Open Access
- 18 July 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (7) , e102197
Abstract
Dendritic cells (DCs) are professional antigen-presenting cells (APCs) in human immune system. DC-based tumor vaccine has met with some success in specific malignancies, inclusive of breast cancer. In this study, we electrofused MDA-MB-231 breast cancer cell line with day-3 DCs derived from peripheral blood monocytes, and explored the biological characteristics of fusion vaccine and its anti-tumor effects in vitro. Day-3 mature DCs were generated from day-2 immature DCs by adding cocktails composed of TNF-α, IL-1β, IL-6 and PEG2. Day-3 mature DCs were identified and electofused with breast cancer cells to generate fusion vaccine. Phenotype of fusion cells were identified by fluorescence microscope and flow cytometer. The fusion vaccine was evaluated for T cell proliferation, secretion of IL-12 and IFN-γ, and induction of tumor-specific CTL response. Despite differences in morphology, day-3 and day-7 DC expressed similar surface markers. The secretion of IL-12 and IFN-γ in fusion vaccine group was much higher than that in the control group. Compared with control group, DC-tumor fusion vaccine could better stimulate the proliferation of allogeneic T lymphocytes and kill more breast cancer cells (MDA-MB-231) in vitro. Day-3 DCs had the same function as the day-7 DCs, but with a shorter culture period. Our findings suggested that day-3 DCs fused with whole apoptotic breast cancer cells could elicit effective specific antitumor T cell responses in vitro and may be developed into a prospective candidate for adoptivet immunotherapy.Keywords
This publication has 25 references indexed in Scilit:
- Dendritic Cells The Tumor Microenvironment and the Challenges for an Effective Antitumor VaccinationJournal of Biomedicine and Biotechnology, 2012
- Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapyJournal of Translational Medicine, 2011
- Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentationJournal of Translational Medicine, 2010
- A new approach for the large-scale generation of mature dendritic cells from adherent PBMC using roller bottle technologyJournal of Immune Based Therapies and Vaccines, 2008
- Breast cancer vaccinesCancer, 2007
- Vaccine immunotherapy in breast cancer treatment: promising, but still earlyExpert Review of Anticancer Therapy, 2007
- A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccinesBMC Cancer, 2007
- Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cellsBreast Cancer Research and Treatment, 2006
- Dendritic Cells in Cancer ImmunotherapyAnnual Review of Immunology, 2000
- Proinflammatory and Immunoregulatory Functions of Interleukin-12International Reviews of Immunology, 1998